NASDAQ: TRAX
First Tracks Biotherapeutics, Inc.CIK 0002091349 · SIC 2834 · Pharmaceutical Preparations
8-Ks, initial S-1s, and selected mega-cap 10-Ks and 10-Qs are open in full. Other reports show a 3-bullet preview; a free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (TPST 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade TRAX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 12, 2026 (period ending Jun 30, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q2 ended Jun 30, 2026 | Q1 ended Mar 31, 2026 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 25.6 | 34.0 |
| General and administrative | 9.3 | 18.9 |
| Total operating expenses | 34.9 | 52.8 |
| Operating income | (34.9) | (52.8) |
| Other income/(expense), net | 1.6 | 2.3 |
| Net income | (33.4) | |
| Basic earnings per share | (0.95) | |
| Diluted earnings per share | (0.95) | |
Consolidated Balance Sheets (Unaudited)
| Description | Jun 30, 2026 | Mar 31, 2026 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 168.0 | 248.5 |
| Short-term investments | — | 38.0 |
| Prepaid expenses and other current assets | 9.7 | 2.9 |
| Total current assets | 177.7 | 289.4 |
| Property, plant and equipment, net | 1.1 | 1.2 |
| Operating lease right-of-use assets, net | 4.3 | — |
| Deferred income taxes and other assets | — | — |
| TOTAL ASSETS | 183.1 | 290.6 |
| Current liabilities: | ||
| Accounts payable | 2.6 | 7.5 |
| Current portion of operating lease liabilities | 2.4 | — |
| Accrued liabilities | 7.5 | 25.6 |
| Total current liabilities | 12.4 | 33.1 |
| Operating lease liabilities | 1.9 | — |
| Shareholders' equity: | ||
| Common stock | 0.04 | |
| Capital in excess of stated value | 193.3 | |
| Accumulated other comprehensive income (loss) | — | (0.1) |
| Retained earnings (deficit) | (24.6) | |
| Total shareholders' equity | 168.8 | 257.5 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 183.1 | 290.6 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended Jun 30, 2026 | Q1 ended Mar 31, 2026 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (64.5) | (32.6) |
| Investing Activities: | ||
| Net cash from investing activities | 35.0 | 35.0 |
| Financing Activities: | ||
| Net cash from financing activities | (40.7) | 7.9 |
| Net increase/(decrease) in cash | (70.2) | 10.3 |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗